Search Results - "Linton, Kim"

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study by Hutchings, Martin, Mous, Rogier, Clausen, Michael Roost, Johnson, Peter, Linton, Kim M, Chamuleau, Martine E D, Lewis, David John, Sureda Balari, Anna, Cunningham, David, Oliveri, Roberto S, Elliott, Brian, DeMarco, Dena, Azaryan, Ada, Chiu, Christopher, Li, Tommy, Chen, Kuo-mei, Ahmadi, Tahamtan, Lugtenburg, Pieternella J

“…Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment options. We aimed to establish the safety and recommended phase 2 dose of…”
Get full text

Primary cilia are increased in number and demonstrate structural abnormalities in human cancer by Yasar, Binnaz, Linton, Kim, Slater, Christian, Byers, Richard

“…Primary cilia play an important role in the regulation of cell signalling pathways and are thought to have a role in cancer but have seldom been studied in…”
Get more information

A clinician’s guide to biosimilars in oncology by Rugo, Hope S, Linton, Kim M, Cervi, Paul, Rosenberg, Julie A, Jacobs, Ira

“…Highlights • A biosimilar is a biological agent that is highly similar to a licensed biologic. • Biosimilars may increase access worldwide to potentially…”
Get full text

Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline by Eyre, Toby A, Bishton, Mark J, McCulloch, Rory, O'Reilly, Maeve, Sanderson, Robin, Menon, Geetha, Iyengar, Sunil, Lewis, David, Lambert, Jonathan, Linton, Kim M, McKay, Pamela

Get full text

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial by Ferreri, Andrés J. M., Cwynarski, Kate, Pulczynski, Elisa, Fox, Christopher P., Schorb, Elisabeth, Celico, Claudia, Falautano, Monica, Nonis, Alessandro, La Rosée, Paul, Binder, Mascia, Fabbri, Alberto, Ilariucci, Fiorella, Krampera, Mauro, Roth, Alexander, Hemmaway, Claire, Johnson, Peter W., Linton, Kim M., Pukrop, Tobias, Gørløv, Jettes Sønderskov, Balzarotti, Monica, Hess, Georg, Keller, Ulrich, Stilgenbauer, Stephan, Panse, Jense, Tucci, Alessandra, Orsucci, Lorella, Pisani, Francesco, Zanni, Manuela, Krause, Stefan W., Schmoll, Hans J., Hertenstein, Bernd, Rummel, Mathias, Smith, Jeffery, Thurner, Lorenz, Cabras, Giuseppina, Pennese, Elsa, Ponzoni, Maurilio, Deckert, Martina, Politi, Letterio S., Finke, Jurgen, Ferranti, Antonella, Cozens, Kelly, Burger, Elvira, Ielmini, Nicoletta, Cavalli, Franco, Zucca, Emanuele, Illerhaus, Gerald

“…219 HIV-negative adults ≤70 years with primary CNS lymphoma (PCNSL) were enrolled in the randomized IELSG32 trial. Enrolled patients were randomly assigned to…”
Get full text

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma by Czuczman, Myron S, Trněný, Marek, Davies, Andrew, Rule, Simon, Linton, Kim M, Wagner-Johnston, Nina, Gascoyne, Randy D, Slack, Graham W, Brousset, Pierre, Eberhard, David A, Hernandez-Ilizaliturri, Francisco J, Salles, Gilles, Witzig, Thomas E, Zinzani, Pier Luigi, Wright, George W, Staudt, Louis M, Yang, Yandan, Williams, P Mickey, Lih, Chih-Jian, Russo, Jacqueline, Thakurta, Anjan, Hagner, Patrick, Fustier, Pierre, Song, Dale, Lewis, Ian D

“…Randomized, multicenter, open-label, phase 2/3 trial investigating lenalidomide versus investigator's choice (IC) in relapsed/refractory diffuse large B-cell…”
Get full text

Pilot study of lung cancer screening for survivors of Hodgkin lymphoma by Broadbent, Rachel, Crosbie, Philip, Armitage, Christopher J, Taylor, Ben, Tenant, Sean, Mercer, Joseph, Radford, John, Linton, Kim

“…Hodgkin lymphoma (HL) treatment increases the risk of lung cancer. Most HL survivors are not eligible for lung cancer screening (LCS) programs developed for…”
Get full text

Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men by Behre, Hermann M, Zitzmann, Michael, Anderson, Richard A, Handelsman, David J, Lestari, Silvia W, McLachlan, Robert I, Meriggiola, M. Cristina, Misro, Man Mohan, Noe, Gabriela, Wu, Frederick C. W, Festin, Mario Philip R, Habib, Ndema A, Vogelsong, Kirsten M, Callahan, Marianne M, Linton, Kim A, Colvard, Doug S

“…Context: The development of a safe and effective reversible method of male contraception is still an unmet need. Objective: Evaluation of suppression of…”
Get full text

Drug-Induced Interstitial Lung Disease: A Systematic Review by Skeoch, Sarah, Weatherley, Nicholas, Swift, Andrew J, Oldroyd, Alexander, Johns, Christopher, Hayton, Conal, Giollo, Alessandro, Wild, James M, Waterton, John C, Buch, Maya, Linton, Kim, Bruce, Ian N, Leonard, Colm, Bianchi, Stephen, Chaudhuri, Nazia

“…Drug-induced interstitial lung disease (DIILD) occurs as a result of numerous agents, but the risk often only becomes apparent after the marketing…”
Get full text

International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma by Khwaja, Jahanzaib, Kirkwood, Amy A, Isbell, Lisa K, Steffanoni, Sara, Goradia, Harshita, Pospiech, Lisa, Fail, Thomas, Nicholson, Emma, Fletcher, Kate, Linton, Kim M, Parsons, Katrina E, Elmusharaf, Nagah, Eccersley, Lydia, Eyre, Toby A, Chaganti, Sridhar, Smith, Jeffrey, Thakrar, Nisha, Kutilina, Alexandra, Calimeri, Teresa, Martinez-Calle, Nicolas, El-Sharkawi, Dima, Osborne, Wendy, Illerhaus, Gerald, Fox, Christopher P, Ferreri, Andrés J M, Schorb, Elisabeth, Cwynarski, Kate

Get full text

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial by Ferreri, Andrés J M, Cwynarski, Kate, Pulczynski, Elisa, Fox, Christopher P, Schorb, Elisabeth, La Rosée, Paul, Binder, Mascha, Fabbri, Alberto, Torri, Valter, Minacapelli, Eleonora, Falautano, Monica, Ilariucci, Fiorella, Ambrosetti, Achille, Roth, Alexander, Hemmaway, Claire, Johnson, Peter, Linton, Kim M, Pukrop, Tobias, Sønderskov Gørløv, Jette, Balzarotti, Monica, Hess, Georg, Keller, Ulrich, Stilgenbauer, Stephan, Panse, Jens, Tucci, Alessandra, Orsucci, Lorella, Pisani, Francesco, Levis, Alessandro, Krause, Stefan W, Schmoll, Hans J, Hertenstein, Bernd, Rummel, Mathias, Smith, Jeffery, Pfreundschuh, Michael, Cabras, Giuseppina, Angrilli, Francesco, Ponzoni, Maurilio, Deckert, Martina, Politi, Letterio S, Finke, Jürgen, Reni, Michele, Cavalli, Franco, Zucca, Emanuele, Illerhaus, Gerald

“…The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in…”
Get full text

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial by Ferreri, Andrés J M, Dr, Cwynarski, Kate, MD, Pulczynski, Elisa, MD, Ponzoni, Maurilio, Prof, Deckert, Martina, Prof, Politi, Letterio S, MD, Torri, Valter, MD, Fox, Christopher P, MD, Rosée, Paul La, MD, Schorb, Elisabeth, MD, Ambrosetti, Achille, Prof, Roth, Alexander, MD, Hemmaway, Claire, MD, Ferrari, Angela, MD, Linton, Kim M, PhD, Rudà, Roberta, MD, Binder, Mascha, Prof, Pukrop, Tobias, Prof, Balzarotti, Monica, MD, Fabbri, Alberto, MD, Johnson, Peter, Prof, Gørløv, Jette Sønderskov, PhD, Hess, Georg, MD, Panse, Jens, MD, Pisani, Francesco, MD, Tucci, Alessandra, MD, Stilgenbauer, Stephan, Prof, Hertenstein, Bernd, MD, Keller, Ulrich, Prof, Krause, Stefan W, Prof, Levis, Alessandro, MD, Schmoll, Hans J, MD, Cavalli, Franco, Prof, Finke, Jürgen, Prof, Reni, Michele, MD, Zucca, Emanuele, MD, Illerhaus, Gerald, Prof

“…Summary Background Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk…”
Get full text

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial by Thieblemont, Catherine, Karimi, Yasmin H, Ghesquieres, Herve, Cheah, Chan Y, Clausen, Michael Roost, Cunningham, David, Jurczak, Wojciech, Do, Young Rok, Gasiorowski, Robin, Lewis, David John, Kim, Tae Min, van der Poel, Marjolein, Poon, Michelle Limei, Feldman, Tatyana, Linton, Kim M, Sureda, Anna, Hutchings, Martin, Dinh, Minh H, Kilavuz, Nurgul, Soong, David, Mark, Thomas, Sacchi, Mariana, Phillips, Tycel, Lugtenburg, Pieternella J

“…Primary results (median follow-up, 10.7 months) from the pivotal EPCORE NHL-1 study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) demonstrated…”
Get full text

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma by Di Ciaccio, Pietro R, Polizzotto, Mark N, Cwynarski, Kate, Gerrie, Alina S, Burton, Catherine, Bower, Mark, Kuruvilla, John, Montoto, Silvia, McKay, Pam, Fox, Christopher P, Milliken, Samuel, Jiamsakul, Awachana, Osborne, Wendy, Collins, Graham P, Manos, Kate, Linton, Kim M, Iyengar, Sunil, Kassam, Shireen, Limei, Michelle Poon, Kliman, David, Wong Doo, Nicole, Watson, Anne-Marie, Fedele, Pasquale, Yannakou, Costas K, Hunt, Stewart, Ku, Matthew, Sehn, Laurie H, Smith, Alexandra, Renshaw, Hanna, Maxwell, Alice, Liu, Qin, Dhairyawan, Rageshri, Ferguson, Graeme, Pickard, Keir, Painter, Daniel, Thakrar, Nisha, Song, Kevin W, Hamad, Nada

“…Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated with immunodeficiency, characterized by uncertain treatment approaches…”
Get full text

The development of a decision aid to support Hodgkin lymphoma survivors considering lung cancer screening by Broadbent, Rachel, Seale, Tania, Armitage, Christopher J, Linton, Kim

“…Decisions aids (DA) can support patients to make informed decisions about screening tests. This study describes the development and initial evaluation of a…”
Get full text

Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial by McIlroy, Graham, Lax, Siân, Gaskell, Charlotte, Jackson, Aimee, Rhodes, Malcolm, Seale, Tania, Fox, Sonia, Hopkins, Lousie, Okosun, Jessica, Barrington, Sally F, Ringshausen, Ingo, Ramsay, Alan G, Calaminici, Maria, Linton, Kim, Bishton, Mark

“…Relapsed or refractory follicular lymphoma (rrFL) is an incurable disease associated with shorter remissions and survival after each line of standard therapy…”
Get full text

A phase II trial of AZD1152 in relapsed/refractory diffuse large B‐cell lymphoma by Collins, Graham P., Eyre, Toby A., Linton, Kim M., Radford, John, Vallance, Grant D., Soilleux, Elizabeth, Hatton, Chris

Get full text

Likely uptake of a future a lung cancer screening programme in Hodgkin lymphoma survivors: a questionnaire study by Broadbent, Rachel, Armitage, Christopher J, Crosbie, Philip, Radford, John, Linton, Kim

“…Many Hodgkin lymphoma (HL) survivors are at increased risk of subsequent malignant neoplasms (SMN), including lung cancer, due to previous treatment for HL…”
Get full text

The perspectives of survivors of Hodgkin lymphoma on lung cancer screening: A qualitative study by Broadbent, Rachel, Gorman, Louise, Armitage, Christopher J., Radford, John, Linton, Kim

“…Background Hodgkin lymphoma survivors (HLS) are at excess risk of lung cancer as a consequence of HL treatment. HLS without a heavy smoking history are…”
Get full text

Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center by Gibb, Adam, Jones, Craig, Bloor, Adrian, Kulkarni, Samar, Illidge, Tim, Linton, Kim, Radford, John

“…The CD30-targeted agent brentuximab vedotin has shown impressive activity in relapsed/refractory Hodgkin lymphoma and anaplastic large cell lymphoma in phase…”
Get full text